Record-Breaking Price Movement
On 09 Apr 2026, Bliss GVS Pharma Ltd’s share price surged to Rs.261.1, surpassing its previous 52-week high of Rs.244.05 by 5.18%. The stock demonstrated robust intraday strength, touching a high that was 3.34% above its weighted average price for the day. This price action was accompanied by a day change of +1.60%, outperforming the Sensex, which declined by 0.23% on the same day.
The stock’s performance over recent sessions has been impressive, with a consecutive two-day gain delivering a cumulative return of 9.72%. Over the last week, the stock outpaced the broader market, rising 9.56% compared to the Sensex’s 5.54% gain. The momentum extended over longer periods as well, with a one-month return of 25.53% and a three-month surge of 46.52%, both significantly ahead of the Sensex’s negative returns during these intervals.
Long-Term Performance Outshines Benchmarks
Bliss GVS Pharma Ltd’s stock has demonstrated remarkable resilience and growth over extended periods. The one-year return stands at an impressive 120.44%, vastly exceeding the Sensex’s 4.79% gain. Year-to-date, the stock has appreciated by 57.00%, while the Sensex has declined by 9.20%. Over three years, the company’s shares have appreciated by 246.14%, dwarfing the Sensex’s 29.33% increase. Even over five and ten years, the stock has delivered strong returns of 153.28% and 83.49%, respectively, underscoring its sustained growth trajectory within the pharmaceuticals sector.
Technical Indicators Signal Bullish Momentum
The technical outlook for Bliss GVS Pharma Ltd remains firmly bullish. The current trend, established on 24 Mar 2026 at a price of Rs.206.85, has strengthened with the stock trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This broad-based technical support highlights the stock’s upward trajectory.
Key technical indicators reinforce this positive stance. Weekly and monthly MACD, Bollinger Bands, KST, Dow Theory, and On-Balance Volume (OBV) all signal bullish momentum. The stock’s immediate support level is anchored at Rs.105.05, the 52-week low, while resistance levels previously at Rs.217.59 (20-day moving average) and Rs.244.05 (52-week high) have been decisively breached, confirming the strength of the current rally.
Valuation Metrics Reflect Reasonable Pricing
As of 09 Apr 2026, Bliss GVS Pharma Ltd’s valuation multiples indicate a balanced pricing environment. The trailing twelve months (TTM) price-to-earnings (P/E) ratio stands at 24x, while the price-to-book value (P/BV) is 2.36x. Enterprise value multiples include EV/EBITDA at 17.96x and EV/EBIT at 23.43x, with an EV/Sales ratio of 2.91x. The PEG ratio is near parity at 1.01x, suggesting that the stock’s price growth is in line with its earnings growth rate.
Dividend metrics show a modest yield of 0.39%, with the latest dividend declared at Rs.0.5 per share and a payout ratio of 6.25%. The ex-dividend date was 18 Feb 2026, reflecting the company’s consistent, albeit conservative, approach to shareholder returns.
Quality Assessment Highlights Financial Stability
Bliss GVS Pharma Ltd is classified as an average quality company based on its long-term financial performance. The company maintains an excellent capital structure with low debt levels, reflected in an average debt-to-EBITDA ratio of 0.78 and a net cash position indicated by a negative net debt-to-equity ratio of -0.13. Institutional holdings are relatively high at 20.33%, signalling confidence from significant market participants.
Sales growth over five years has been steady at 8.97% CAGR, while EBIT growth is more modest at 3.85%. The company’s return on capital employed (ROCE) averages 12.28%, and return on equity (ROE) is 9.42%, both considered on the weaker side but consistent with the company’s profile. The dividend payout ratio remains low, supporting reinvestment and balance sheet strength.
Recent Financial Trends and Delivery Volumes
Short-term financial trends as of December 2025 indicate a flat trajectory, with some positive highlights such as the highest half-year ROCE of 14.76% and a low debt-equity ratio of 0.05 times. Profit after tax (PAT) for the nine months reached ₹95.08 crores, reflecting solid profitability. However, interest expenses have increased by 51.75% to ₹10.00 crores, and the debtors turnover ratio remains low at 1.75 times.
Delivery volumes have shown an upward trend, with a 1-month delivery change of 25.07% and a 1-day delivery change of 32.41% compared to the 5-day average. On 08 Apr 2026, the volume was 11.39 lakh shares, representing 40.46% of total volume, above the trailing one-month average of 8.01 lakh shares.
Sector Outperformance and Market Capitalisation
Bliss GVS Pharma Ltd operates within the Pharmaceuticals & Biotechnology sector, where it has consistently outperformed sector benchmarks. On the day of the all-time high, the stock outperformed its sector by 2.66%. The company is classified as a micro-cap entity, reflecting its market capitalisation relative to larger peers in the industry.
The stock’s recent upgrade in rating by MarketsMOJO from Sell to Hold on 12 Nov 2025, with a current Mojo Score of 60.0 and a Hold grade, aligns with its improved market performance and technical strength. This rating reflects a balanced view of the company’s valuation and growth prospects as of the latest assessment.
Summary of Key Price and Performance Metrics
Price Summary as of 09 Apr 2026:
- All-Time High Price: Rs.261.1
- 52-Week High: Rs.244.05
- 52-Week Low: Rs.105.05
- Current Price Distance from High: +5.18%
- Current Price Distance from Low: +144.36%
- Intraday Volatility: 8.12%
- Consecutive Gains: 2 days with 9.72% returns
Performance Comparison with Sensex:
- 1 Day: +1.60% vs Sensex -0.23%
- 1 Week: +9.56% vs Sensex +5.54%
- 1 Month: +25.53% vs Sensex -0.24%
- 3 Months: +46.52% vs Sensex -7.41%
- 1 Year: +120.44% vs Sensex +4.79%
- Year to Date: +57.00% vs Sensex -9.20%
- 3 Years: +246.14% vs Sensex +29.33%
- 5 Years: +153.28% vs Sensex +56.04%
- 10 Years: +83.49% vs Sensex +213.62%
These figures underscore the stock’s exceptional performance relative to the broader market and its sector peers.
